Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Hsu

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Cancer Chemotherapy and Pharmacology|May 13, 2016
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphomaOliver E Bechter, Herlinde Dumez, Jo Costermans, et al.
Blood|March 5, 2004
The pu.1 promoter drives myeloid gene expression in zebrafishKarl Hsu, David Traver, Jeffery L Kutok, et al.
Experimental Hematology & Oncology|November 22, 2014
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trialTeresa Moran, Enriqueta Felip, Vicki Keedy, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2017
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumoursMaja de Jonge, Vincent A de Weger, Mark A Dickson, et al.
British Journal of Cancer|December 27, 2018
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumoursVincent A de Weger, Maja de Jonge, Marlies H G Langenberg, et al.
Cancer Research Communications|March 27, 2023
CD47-blocking Antibody ZL-1201 Promotes Tumor-associated Macrophage Phagocytic Activity and Enhances the Efficacy of the Therapeutic Antibodies and ChemotherapyAnthony Cao, Jiaqing Yi, Xinyan Tang, et al.
Nature Medicine|December 13, 2006
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformationTing Xi Liu, Michael W Becker, Jaroslav Jelinek, et al.
Cancer Research Communications|March 16, 2023
ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer ModelsHiroyasu Konno, Tracey Lin, Renyi Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2011
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumorsFrancesco Atzori, Josep Tabernero, Andrés Cervantes, et al.
Oncoimmunology|September 6, 2021
Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatmentHélène Bonnevaux, Stephane Guerif, Jana Albrecht, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Cancer Chemotherapy and Pharmacology|May 13, 2016
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphomaOliver E Bechter, Herlinde Dumez, Jo Costermans, et al.
Blood|March 5, 2004
The pu.1 promoter drives myeloid gene expression in zebrafishKarl Hsu, David Traver, Jeffery L Kutok, et al.
Experimental Hematology & Oncology|November 22, 2014
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trialTeresa Moran, Enriqueta Felip, Vicki Keedy, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2017
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumoursMaja de Jonge, Vincent A de Weger, Mark A Dickson, et al.
British Journal of Cancer|December 27, 2018
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumoursVincent A de Weger, Maja de Jonge, Marlies H G Langenberg, et al.
Cancer Research Communications|March 27, 2023
CD47-blocking Antibody ZL-1201 Promotes Tumor-associated Macrophage Phagocytic Activity and Enhances the Efficacy of the Therapeutic Antibodies and ChemotherapyAnthony Cao, Jiaqing Yi, Xinyan Tang, et al.
Nature Medicine|December 13, 2006
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformationTing Xi Liu, Michael W Becker, Jaroslav Jelinek, et al.
Cancer Research Communications|March 16, 2023
ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer ModelsHiroyasu Konno, Tracey Lin, Renyi Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2011
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumorsFrancesco Atzori, Josep Tabernero, Andrés Cervantes, et al.
Oncoimmunology|September 6, 2021
Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatmentHélène Bonnevaux, Stephane Guerif, Jana Albrecht, et al.
Pageof 3